WS016
Phase 2Small molecule
WS016 is one of 8 small molecule programs targeting Hyperkalemia. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Hyperkalemia
#DrugCompanyPhaseTrials
1Salbutamol
GSKApproved
Insulin 320
Novo NordiskApproved
Veltassa
VVifor Pharma
Phase 3
Sodium Valproate
AstraZenecaPhase 3
Insulin Regular
TThe University of Texas Medical Branch, Galveston
Approved
Zirconium Silicate (ZS)
ZZS Pharma, Inc.
Phase 3
WS016
WWaterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 2
Sodium Polystyrene Sulfonate
ZZS Pharma, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for WS016. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details